Literature DB >> 21208977

Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus.

Takahisa Gono1, Yasushi Kawaguchi, Hirotaka Kaneko, Katsuji Nishimura, Masanori Hanaoka, Sayuri Kataoka, Yuko Okamoto, Yasuhiro Katsumata, Hisashi Yamanaka.   

Abstract

OBJECTIVE: The aim of this study is to establish a detection method for anti-N-methyl-d-aspartate receptor subunit 2A (NR2A) antibody and to evaluate the relationship between anti-NR2A antibody and various organ involvement in SLE.
METHODS: Serum anti-NR2A antibody was measured by ELISA using a peptide with a core of either DWEYS or DWDYS as autoantigen. Additionally, clinical characteristics were compared between 27 anti-NR2A antibody-positive (P group) and 80 antibody-negative (N group) SLE patients using DWDYS peptide.
RESULTS: The optical density (OD) values of anti-NR2A antibody using DWDYS and DWEYS peptides correlated significantly (r = 0.94, P < 0.0001). The median OD value was significantly higher (P < 0.0001) with DWDYS. Additionally, the SLEDAI was significantly higher (P = 0.023) in the P group. The frequency of neuropsychiatric SLE (NPSLE) was significantly higher (P = 0.0002) in the P group, although the frequencies of serositis and nephritis were not statistically significant. Significant correlations were found between anti-NR2A antibody and leucocyte count (r(s) = -0.31, P = 0.001) and haemoglobin (r(s) = -0.42, P < 0.0001), although no correlation was found between anti-NR2A antibody and the titre of anti-dsDNA antibody. NPSLE was the most significant independent variable (P = 0.0008) associated with anti-NR2A antibody positivity, as estimated by multiple linear regression analysis.
CONCLUSION: Serum anti-NR2A antibody can be associated with the complication of NPSLE and may indicate the involvement of non-nervous tissue. The use of peptides that include DWDYS is preferable to detect anti-NR2A antibody in ELISA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21208977     DOI: 10.1093/rheumatology/keq408

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  27 in total

Review 1.  A model for lupus brain disease.

Authors:  Betty Diamond; Bruce T Volpe
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 2.  The Functional and Molecular Properties, Physiological Functions, and Pathophysiological Roles of GluN2A in the Central Nervous System.

Authors:  Yongjun Sun; Xiaokun Cheng; Linan Zhang; Jie Hu; You Chen; Liying Zhan; Zibin Gao
Journal:  Mol Neurobiol       Date:  2016-01-21       Impact factor: 5.590

3.  Libman-Sacks endocarditis and embolic cerebrovascular disease.

Authors:  Carlos A Roldan; Wilmer L Sibbitt; Clifford R Qualls; Rex E Jung; Ernest R Greene; Charles M Gasparovic; Reyaad A Hayek; Gerald A Charlton; Kendall Crookston
Journal:  JACC Cardiovasc Imaging       Date:  2013-09

Review 4.  Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review.

Authors:  Savino Sciascia; Maria Laura Bertolaccini; Dario Roccatello; Munther A Khamashta; Giovanni Sanna
Journal:  J Neurol       Date:  2014-06-21       Impact factor: 4.849

5.  Depression with psychotic features in a child with SLE: successful therapy with psychotropic medications--case report.

Authors:  Milica Pejovic Milovancevic; Vladimir Miletic; Smiljka Popovic Deusic; Saveta Draganic Gajic; Dusica Lecic Tosevski
Journal:  Eur Child Adolesc Psychiatry       Date:  2012-10-10       Impact factor: 4.785

6.  [NMDAR autoantibodies as biomarker for fatigue in SLE].

Authors:  M A Schramm; N Venhoff
Journal:  Z Rheumatol       Date:  2020-02       Impact factor: 1.372

7.  Alterations in Blood-Brain Barrier Permeability in Patients with Systemic Lupus Erythematosus.

Authors:  J M Chi; M Mackay; A Hoang; K Cheng; C Aranow; J Ivanidze; B Volpe; B Diamond; P C Sanelli
Journal:  AJNR Am J Neuroradiol       Date:  2019-02-21       Impact factor: 3.825

Review 8.  Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome.

Authors:  José Fidel Baizabal-Carvallo; Cecilia Bonnet; Joseph Jankovic
Journal:  J Neural Transm (Vienna)       Date:  2013-04-13       Impact factor: 3.575

Review 9.  Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus.

Authors:  Virginia Fernandes Moça Trevisani; Aldemar A Castro; João Ferreira Neves Neto; Alvaro N Atallah
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 10.  Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.

Authors:  Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-08-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.